Blake Borgeson Sells 220,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 220,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $4.20, for a total transaction of $924,000.00. Following the sale, the director directly owned 6,429,863 shares of the company’s stock, valued at approximately $27,005,424.60. This trade represents a 3.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, January 6th, Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $4.36, for a total transaction of $959,200.00.
• On Tuesday, December 2nd, Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $4.37, for a total transaction of $961,400.00.

Recursion Pharmaceuticals Trading Up 11.8%

RXRX opened at $3.98 on Friday. The company has a fifty day moving average price of $4.45 and a two-hundred day moving average price of $4.92. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.54 and a 1-year high of $12.36. The company has a market cap of $2.07 billion, a P/E ratio of -2.21 and a beta of 0.95. The company has a current ratio of 4.60, a quick ratio of 4.60 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. The company had revenue of $5.18 million for the quarter, compared to analysts’ expectations of $19.36 million. During the same quarter in the prior year, the firm earned ($0.34) EPS. The business’s revenue was down 80.1% on a year-over-year basis. Analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Ratings Changes

RXRX has been the topic of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, January 22nd. Morgan Stanley set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. UBS Group set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Finally, JPMorgan Chase & Co. upgraded shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $10.00 to $11.00 in a report on Wednesday, December 17th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $9.40.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several large investors have recently bought and sold shares of RXRX. Clear Creek Financial Management LLC boosted its holdings in Recursion Pharmaceuticals by 10.0% in the 2nd quarter. Clear Creek Financial Management LLC now owns 23,442 shares of the company’s stock worth $119,000 after buying an additional 2,127 shares during the period. TD Waterhouse Canada Inc. lifted its position in shares of Recursion Pharmaceuticals by 64.1% during the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock worth $29,000 after acquiring an additional 2,200 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Recursion Pharmaceuticals by 16.8% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,439 shares of the company’s stock worth $78,000 after acquiring an additional 2,219 shares in the last quarter. Xponance Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 8.0% in the third quarter. Xponance Inc. now owns 30,020 shares of the company’s stock worth $146,000 after acquiring an additional 2,221 shares during the period. Finally, Main Management ETF Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 142,914 shares of the company’s stock worth $723,000 after acquiring an additional 2,328 shares during the period. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.